News

British Columbia Cancer Agency study reconfirms: high efficacy combined with very low side effects makes brachytherapy the treatment of choice for localized prostate cancer.

Topics related to early detection, modern diagnostics and therapy of prostate diseases were the focus of the "12th Patient Day Prostate" on June 4, 2019 in Cologne, attended by about 200 interested and affected persons at the invitation of the West German Prostate Center.

Patients with type 2 diabetes are less likely to develop prostate cancer. On the other hand, their prognosis is worse when prostate cancer is diagnosed. Afterloading therapy achieves the best results in advanced-stage tumors.

International metastudy: brachytherapy at least equivalent or superior to radical surgery.

Great advantage for patients who are dependent on anticoagulant medication.

As one of the highest-case volume centers in Europe, the WPZ specializes in prostate treatment.

COPCa study: which treatment do patients with low-risk prostate cancer choose?

Significant decrease in mortality and metastasis in PSA-tested men.

Recent results from the two-year SPIRIT trial demonstrate clear benefits for brachytherapy.

Prostate cancer patients benefit from intensive follow-up at the West German Prostate Center.

Dr. Derakhshani on the possibilities and limitations of focal therapy.

Experimental method with risk of overtherapy.